Target Discovery - Isonostics™ Opportunities in the Cancer Diagnostics Market

Home

Main Menu

Home
About TDI
Isonostic™ Products
Corporate Communications
Careers
Contact Us
Site Map

PDF Viewer

Adobe Reader 6.0 or higher is required to view our PDF documents.

Target Discovery discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and management of disease. A growing body of scientific literature shows that protein isoforms correlate more precisely with disease state and patient-specific treatment response than current clinical biomarkers. Most protein isoforms (90%) are made by the body after the protein is produced (post-translational modifications). Such protein modifications remain largely inaccessible to current immunodiagnostic and nucleic acid clinical assays. Target Discovery's Isonostic™ products are designed to make this isoform biomarker information accessible to clinicians.

Learn More About Protein Isoforms